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Testing for sexually transmitted infections in
a population-based sexual health survey:
development of an acceptable ethical approach
Nigel Field,1 Clare Tanton,1 Catherine H Mercer,1 Soazig Nicholson,2 Kate Soldan,3
Simon Beddows,3 Catherine Ison,3 Anne M Johnson,1 Pam Sonnenberg1
ABSTRACT
Population-based research is enhanced by biological
measures, but biological sampling raises complex ethical
issues. The third British National Survey of Sexual
Attitudes and Lifestyles (Natsal-3) will estimate the
population prevalence of five sexually transmitted
infections (STIs) (Chlamydia trachomatis, Neisseria
gonorrhoeae, human papillomavirus (HPV), HIV and
Mycoplasma genitalium) in a probability sample aged
16e44 years. The present work describes the
development of an ethical approach to urine testing for
STIs, including the process of reaching consensus on
whether to return results. The following issues were
considered: (1) testing for some STIs that are treatable
and for which appropriate settings to obtain free testing
and advice are widely available (Natsal-3 provides all
respondents with STI and healthcare access
information), (2) limits on test accuracy and timeliness
imposed by survey conditions and sample type, (3)
testing for some STIs with unknown clinical and public
health implications, (4) how a uniform approach is easier
to explain and understand, (5) practical difficulties in
returning results and cost efficiency, such as enabling
wider STI testing by not returning results. The agreed
approach, to perform voluntary anonymous testing with
specific consent for five STIs without returning results,
was approved by stakeholders and a research ethics
committee. Overall, this was acceptable to respondents
in developmental piloting; 61% (68 of 111) of
respondents agreed to provide a sample. The
experiences reported here may inform the ethical
decision making of researchers, research ethics
committees and funders considering population-based
biological sampling.
INTRODUCTION
Testing of biological samples in epidemiological
research raises important ethical questions.1 The
issues are particularly complex when applied to
sexually transmitted infections (STIs) because of the
stigma associated with diagnosis and the impor-
tance of conﬁdentiality.2 Researchers are also faced
with the decision of whether and when to disclose
results to research participants.3 This paper
describes the development of an ethical approach to
urine-based STI testing in the third British National
Survey of Sexual Attitudes and Lifestyles (Natsal-3).
Natsal-3 is a probability sample of 15 000 adults
aged 16e74 years in Britain for which survey
ﬁeldwork started in 2010. It follows previous
Natsal surveys in 1990 and 2000.4 5 The survey
collects behavioural data, including sexual activity,
partnership patterns, sexual function and health
outcomes. In addition, Natsal-3 employs urine-
based testing to estimate prevalence of Chlamydia
trachomatis, Neisseria gonorrhoeae, human papillo-
mavirus (HPV), HIV and Mycoplasma genitalium in
a subgroup of 5000 respondents aged 16e44 years.
Benefits of biological testing in population-based
research
Linking biological information to behavioural and
demographic data can strengthen population-based
research. For example, in 2000, Natsal-2 measured
urinary C trachomatis prevalence, which informed
the decision to extend national screening to men.6
Among many others, national surveys such as the
UK Biobank, Health Survey for England (HSE), the
English Longitudinal Study of Ageing (ELSA),
the USA Health and Retirement Study (HRS) and
the National Health and Nutrition and Examination
Survey (NHANES) collect biological samples for
biomarkers of disease. Biomarkers are not subject to
reporting bias and lend considerable weight to the
scientiﬁc reliability and precision of data, and may
be used to validate self-reporting.7 These studies
inform a wide range of health-related activities.
An ethical framework for biological testing in
population-based research
Biological testing in population-based research also
raises important ethical considerations, for which
the bioethical principles (autonomy, beneﬁcence,
non-maleﬁcence and justice), set out by Beauchamp
and Childress, provide a framework.8 Beauchamp
and Walters also identiﬁed four secondary princi-
ples: ‘ﬁdelity ’, ‘conﬁdentiality ’, ‘utility ’ and
‘veracity ’.9 The WHO and Joint United Nations
Programme on HIV/AIDS (UNAIDS) applied these
standards to guide the design of population-based
surveys measuring HIV prevalence.10 First, respon-
dents should ‘be protected from any harm’, which
includes safeguarding respondent conﬁdentiality.
Second, respondents should ‘participate in the
beneﬁts of the research’. This is more complex
because there may be no direct beneﬁts for
respondents in population-based surveys, but
rather indirect societal beneﬁts.11 12 Direct clinical
beneﬁts may occur where results are returned to
respondents with advice and/or treatment.
WHO/UNAIDS guidelines therefore suggest
referral to free testing where results are not
returned.10 Third, respondents should ‘be informed
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of the procedures and risks’. And fourth, respondents should
‘freely choose whether or not to participate in the study’.
International guidelines for HIV testing have distinguished
between unlinked anonymous testing (UA), where results are
irreversibly unlinked from the person tested, and linked testing,
where results may or may not be returned.13 A programme of
UA HIV surveillance testing has been successfully in place in the
UK since 1990.14 However, the UA surveys differ from Natsal-3
in two key respects; (1) the UA research programme is not the
primary reason for obtaining the sample tested, which is
a routine sample and would otherwise have been discarded, and
(2) individual consent for HIV testing on the leftover blood
samples is not usually required.10
Whether to return STI results in Natsal-3
Focus group studies suggest signiﬁcant public interest in indi-
vidual results from genetic research studies,15 but no studies
have directly investigated preferences for obtaining results in the
context of population-based STI research.
In designing Natsal-3, the decision to return STI results or
not was an ethical concern because harm to respondents and
their sexual partners might be avoided by returning results for
treatable infections. Full disclosure is also consistent with
upholding respect for respondents, and includes those wishing
to participate only where results are returned.16 We considered
the risks associated with not returning STI results against the
alternative risks if named testing was conducted and results
were returned.
METHODS
We undertook an extensive development phase to agree and test
the acceptability and feasibility of STI testing in Natsal-3. The
ethical principles described above informed our initial approach
during the study funding process, and this was endorsed via
independent peer review. An informed consensus was then
sought through consultation with stakeholders including the
Health Protection Agency (HPA), clinicians and the study ’s
Advisory Group (which includes representatives from the
Terrence Higgins Trust, Family Planning Association and UK
Department of Health). The approach was submitted to a NHS
research ethics committee (REC) before piloting of the whole
survey was undertaken in 23 postcode sectors across Great
Britain. Within each sector, 25 addresses were randomly selected
to yield a total sample of 575 addresses, of which 434 were
residential with English-speaking and eligible occupants (aged
16e74 years). Interviews took place between March and May
2010. The response rate was 50.2%: 111 respondents aged
16e44 years reporting at least one sexual partner were invited to
provide a urine sample.
RESULTS
The availability of free STI tests in Britain
For some STIs, there are speciﬁc recommended treatments with
direct clinical beneﬁts (table 1). However, it was argued that
speciﬁc written details describing access to and availability of
STI/HIV testing, as well as general sexual health information
could be provided to respondents, and that these services provide
a more appropriate setting for free diagnostic testing than is
possible for Natsal-3. For C trachomatis, there is now widespread
testing in the community, and for young people since 2003,
a national screening programme, such that an estimated 22.1%
of 15e24 year olds were screened in 2010.18 Sexual health
screening was less accessible in 2000, when Natsal-2 did return
C trachomatis results.19
Accuracy and timeliness of survey tests
As in other surveys, the tests used in Natsal-3 may not reach the
required level of clinical diagnostic accuracy, while still being
sufﬁciently accurate for population prevalence estimates (table
1). Under study conditions some loss in sensitivity is expected,
due to limitations on the specimen type and the need to
transport, freeze and batch test samples, which may result in
clinically unacceptable delays. The standard of diagnostic accu-
racy is a concern for all respondents. For example, a null or
negative result feedback might result in undue reassurance and
be without the health education messages that can be delivered
when this occurs in a clinical setting. Providing STI test results,
where the prevalence and therefore positive predictive values
may be low raises the possibility of false positives, which would
also cause harm through undue concern (table 1).
Results with unknown clinical and public health implications
For HPV and M genitalium, the clinical and public health impli-
cations currently remain uncertain, such that a positive result
may not require speciﬁc management, treatment or partner
notiﬁcation and may cause unnecessary and unethical distress
(table 1).
A consistent approach supports effective communication
Providing results for some STIs, but not others, may be misin-
terpreted in that respondents may wrongly assume the results
to apply to all STIs. A thorough understanding of the study
design is a prerequisite for obtaining informed consent from
respondents, and we argued that a uniform approach to test
Table 1 Whether or not to return STI results for the third British National Survey of Sexual Attitudes and
Lifestyles (Natsal-3): infection-specific issues (as of 2009)
Free NHS
testing available
Clinical standard for
treatment available
Prevalence of
undiagnosed infections
Sample type and
testing is of clinical
diagnostic standard
Chlamydia trachomatis Yes Yes High No*
Neisseria gonorrhoeae Yes Yes Low No*
HIV Yes Yes Lowy No
HPV Noz No High NAx
Mycoplasma genitalium Noz No Unknown NAx
Bold type shows factors that favour named testing.
*Due to delay and batch testing.
yThe Health Protection Agency estimates that 24% of HIV-infected people are unaware of their infection in the UK.17
zNot usually performed.
xA clinical standard for testing is not currently available.
HPV, human papillomavirus; NA, not applicable; STI, sexually transmitted infection.
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results is easier to communicate, both for interviewers to explain
and for respondents to understand.
Practical considerations and cost efficiency
In Natsal-2, where C trachomatis prevalence was approximately
2%, a research nurse was employed to actively follow-up
cases.6 19 Even with considerable effort, it proved impossible to
contact 11% of cases with their results, and clinical outcomes
were only available in half of contacted cases. Other authors
have acknowledged the human and ﬁnancial cost associated with
appropriate return of results.15 For Natsal-3, non-return was
argued to enable testing of a wider range of infections to identify
coinfection and associated risk factors. We reasoned that maxi-
mising the scientiﬁc output from biological testing is desirable,
provided ethical principles are not compromised, and is consis-
tent with an obligation to spend public research funds wisely.
Acceptability
In piloting, 61% (68 of 111) of respondents agreed to provide
a urine sample without receiving results. In Natsal-2, in 2000,
when C trachomatis results were given, 71% of participants agreed.6
Few respondents raised concerns that results would not be
returned. Some respondents were reassured after discussing their
concerns with the interviewer. Data from the developmental phase
were used to inform the study design and the patient information
literature, and to support subsequent REC applications.
DISCUSSION
This paper describes the development of, and basis for, an ethi-
cally sound approach to STI testing within a large, population-
based survey. Our approach was guided by ethical, practical and
scientiﬁc principles and considerations. The testing of STIs and
the decision not to return results was accepted by a REC, within
the context that respondents were informed about and
consented to this methodology. Although there are not direct
beneﬁts to participation, voluntary anonymised testing, with
speciﬁc consent for this, including the knowledge that results
will not be returned, was acceptable to respondents when
piloted in Natsal-3.
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